COST UTILITY ANALYSIS OF INFLIXIMAB FOR THE TREATMENT OF SEVERE RHEUMATOID ARTHRITIS IN THAILAND
Author(s)
Tangwongsiri D1, Leartsakulpanitch J2
1Janssen-Cilag (Thailand) Limited, Bangkok, Thailand, 2Janssen Asia Pacific, Singapore, Singapore
Presentation Documents
OBJECTIVES: To evaluate the cost-utility of Infliximab plus methotrexate (MTX) compared with MTX alone, in severe rheumatoid arthritis (RA) patients who were intolerant or inadequately responded to conventional DMARDs including MTX which is available in the national list of essential medicine (NLEM) in Thailand. METHODS: A Markov model consisting of Markov states defined by the disease activity score 28 (DAS28) was developed to reflect the clinical assessment in the treatment of RA in Thailand. Markov states for remission (DAS < 2.6), low disease activity (DAS 2.6-3.2), moderate disease activity (DAS 3.2-5.1), high disease activity (DAS ≥ 5.1), and dead were defined. With a cycle length of 6 months, transition probabilities were estimated based on ACR response in the clinical trial which was assumed to directly represent changes in disease severity. DAS28 was assumed to be a clinically appropriate proxy for utility estimation (EQ5D). Both direct and indirect costs including patient’s income loss were calculated under societal perspective. Data source of resource use are mainly based on estimation by experts. Cost and outcomes were discounted at 3%. One-way and probabilistic sensitivity analysis were conducted to test the robustness of the results. RESULTS: Infliximab plus MTX had an ICER of 131,867 baht per QALY gained compared to MTX alone. This falls into the range of acceptable ICER within 1-3 times of GDP per capita in Thailand (120,000 – 360,000 baht per QALY gained). The probability of cost-effective for Infliximab was presented at 8%, 50%, and 70% at the willingness-to-pay of 120,000 baht, 240,000 baht, and 360,000 baht per QALY gained respectively. CONCLUSIONS: This model suggests, with its underlying assumption, that Infliximab plus MTX seems to be more cost-effective treatment than MTX alone for Thai patients with severe RA that cannot be controlled by conventional DMARDs.
Conference/Value in Health Info
2014-09, ISPOR Asia Pacific 2014, Beijing, China
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PMS18
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Musculoskeletal Disorders